Dr. Robert D. Fishberg, MD

Medicare patients and services

Medicare patients, 2024

1,151

Services billed

3,158

Patients’ average age

76

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 23 companies reported 149 payments worth $26,603 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New Jersey →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $804,077 in research payments for these studies, mostly to the institutions running them.

• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
  Eli Lilly and Company · Active, not recruiting · NCT06292013
• A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
  Amgen Inc.
• A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]
  Novartis Pharmaceuticals Corporation
• A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
  Novartis Pharmaceuticals Corporation
• A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascula…
  Novartis Pharmaceuticals Corporation
• Atlantic lipid lowering treatment optimization program (alltop): a comprehensive approach to addressing dyslipidemia and comorbidities among high-risk patients
  Regeneron Pharmaceuticals, Inc.
• A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
  Novartis Pharmaceuticals Corporation
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
  Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Cardiology clinicians in Springfield

• Michael S. Lux, MD
• Kevin M. Mcelligott, M.D.
• David E. Powell, MD
• Sanjiv Prasad, MD
• Roberto R. Roberti
• Elliott M. Stein, MD
• Vance J. Weber, MD
• Michael Weinrauch, MD